asinn
voted
Hi, mooers!
Just a heads-up:
Earnings Challenge is in full swing! What's your take on Apple's earnings and its stock performance? Now join the challenge, leverage moomoo's handy features to support your views on Apple and earn plenty of rewards! Don't miss the chance to win big>>
$Apple(AAPL.US$ is releasing its Q3 FY2024 earnings on August 1 after the bell. Unlock insights with Apple Earnings Hub>>
For the details of i...
Just a heads-up:
Earnings Challenge is in full swing! What's your take on Apple's earnings and its stock performance? Now join the challenge, leverage moomoo's handy features to support your views on Apple and earn plenty of rewards! Don't miss the chance to win big>>
$Apple(AAPL.US$ is releasing its Q3 FY2024 earnings on August 1 after the bell. Unlock insights with Apple Earnings Hub>>
For the details of i...
99
191
asinn
voted
$Tesla(TSLA.US$ is releasing its Q2 earnings on July 23 after the bell. Unlock insights with TSLA Earnings Hub>>
For the details of indicator sentiment, please tap the link and check.
Since its Q1 earnings release, shares of $Tesla(TSLA.US$ have seen an increase of 72.26%! How will the market react to the upcoming results? Make your guess now!
Rewards
● An equal share of 10,000 points: For mooers who correctly guess th...
For the details of indicator sentiment, please tap the link and check.
Since its Q1 earnings release, shares of $Tesla(TSLA.US$ have seen an increase of 72.26%! How will the market react to the upcoming results? Make your guess now!
Rewards
● An equal share of 10,000 points: For mooers who correctly guess th...
Expand
122
245
asinn
commented on
Good morning mooers! Here are things you need to know about today's Singapore:
●Singapore shares opened lower on Monday; STI down 1.01%
●Commodities face tough week as Fed angst builds
●Stocks and REITs to watch: Singtel, SPH Reit, Aspen
●Latest share buy back transactions
-moomoo News SG
Market Trend
Singapore shares opened lower on Monday. The $FTSE Singapore Straits Time Index(.STI.SG$ decreased 1.01 per cent to 3,114.16 ...
●Singapore shares opened lower on Monday; STI down 1.01%
●Commodities face tough week as Fed angst builds
●Stocks and REITs to watch: Singtel, SPH Reit, Aspen
●Latest share buy back transactions
-moomoo News SG
Market Trend
Singapore shares opened lower on Monday. The $FTSE Singapore Straits Time Index(.STI.SG$ decreased 1.01 per cent to 3,114.16 ...
1443
1387
asinn
commented on
The past week has been a dark period in the history of crypto, with the total market capitalization of this industry dipping as low as $1.2 trillion for the first time since July 2021. The turmoil, in large part, has been due to the real-time disintegration of $Terra(LUNA.CC$.
Last week, Terra has officially stopped block production as the blockchain's native token hit a low of $0.0003, near zero.
In a tumble start...
Last week, Terra has officially stopped block production as the blockchain's native token hit a low of $0.0003, near zero.
In a tumble start...
1093
961
asinn
commented on
Singapore real estate investment trusts can benefit from their safe-haven status during a time of market volatility as the U.S. Fed raises interest rates, analysts from DBS say in a research note.
The Fed's clarity on its rate-rise trajectory will likely lead to more price stability for Singapore REITs, they say.
What are Real Estate Investment Trusts (REITs)?
Real Estate Investment Trusts (REITs) are funds that invest in a port...
The Fed's clarity on its rate-rise trajectory will likely lead to more price stability for Singapore REITs, they say.
What are Real Estate Investment Trusts (REITs)?
Real Estate Investment Trusts (REITs) are funds that invest in a port...
1536
1277
asinn
liked
$Pfizer(PFE.US$ announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.
The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.
BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.
Broad Label, Increased Supply To Give Pfizer Dominant Market Position: Pfizer received the nod for the oral COVID-19 treatment ahead of $Merck & Co(MRK.US$ , which submitted its application for its molnupiravir more than a month ahead of Pfizer, Porges said in a note.
The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.
Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.
Paxlovid Should Remain A Steady Contributor, BofA Says: There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.
The Pfizer Analysts: SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.
BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.
Broad Label, Increased Supply To Give Pfizer Dominant Market Position: Pfizer received the nod for the oral COVID-19 treatment ahead of $Merck & Co(MRK.US$ , which submitted its application for its molnupiravir more than a month ahead of Pfizer, Porges said in a note.
The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.
Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.
Paxlovid Should Remain A Steady Contributor, BofA Says: There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.
21
asinn
reacted to
$Coinbase(COIN.US$ Can't Moo Moo buy Bitcoin?
Translated
3
5